DS Healthcare launches Spectral.DNC-N, first-of-its-kind product to help prevent thinning hair
Biotechnology advances propel everyday hair care
Pompano Beach, May 2, 2013 (GLOBE NEWSWIRE) — DS Healthcare Group Inc. (DSKX), a leading developer of personal care products, announced today the launch of Spectral.DNC-N, the first product to incorporate the proprietary Nanoxidil compound, a powerful, gentle, nondrug alternative to minoxidil.
The new product is formulated to help stimulate hair across the entire scalp. It employs the Nanosome-encapsulation system — proprietary to the company’s DS Laboratories brand — to transport ingredients deeper into follicles for more effective results.
Spectral.DNC-N is the latest addition to the Spectral line, the first topical treatment series to address more than 20 potential causes of hair thinning and loss. Spectral products target these challenges with multiple bioactive ingredients to promote follicle rejuvenation throughout the entire scalp, as minoxidil does at the vertex.
The new formula was created to surpass the results obtained from older products. The innovative, nondrug biotechnology is lightweight, easy to use, and does not leave a heavy, greasy, or unsightly residue, which is common with mass-market hair-growth products.
In the hair follicle, Spectral.DNC-N generates adenosine triphosphate, the universal currency of bioenergy, and deposits a multitude of key compounds via sophisticated delivery systems. The formula is anti-inflammatory and antihormonal and delivers hydration, nutrition, stimulation, and rejuvenation.
New Nanoxidil 5%, a key compound in the product, has a lower molecular weight and does not require the chemical solvents that often irritate scalp. It works well for women with noticeable thinning and for men in the early or moderate stages of thinning. It benefits users with receding hairlines or patchy eyebrows and serves as an overall preventative therapy.
Uniquely lightweight and comfortable to use, Spectral.DNC-N contains procyanidin B-2 (apple polyphenol) to encourage hairline as well as vertex growth, retinol for better absorption, adenosine for cellular repair, patented Aminexil(R) to counter perifollicular fibrosis, copper peptides to fight scalp inflammation, and herbal extracts to support a healthy and comfortable overall condition.
About DS Healthcare Group
DS Healthcare Group Inc. leads in the development of biotechnology for topical, and nutritional therapies. It markets through online and specialty retailers, distributors, cosmetics wholesalers, and salons. Its brands include DS Laboratories (www.DSLaboratories.com), Sigma Skin (www.SigmaSkin.com), Polaris Research Laboratories (www.PolarisReserachLabs.com) and The Pure Guild (www.ThePureGuild.com).
Forward-looking statements
Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies, and are generally preceded by words such as “future,” “plan” or “planned,” “expects,” or “projected.” These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company’s control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing and marketing products, intense competition, and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available at http://www.sec.gov.
DS Healthcare launches Spectral.DNC-N, first-of-its-kind product to help prevent thinning hair
Biotechnology advances propel everyday hair care
Pompano Beach, May 2, 2013 (GLOBE NEWSWIRE) — DS Healthcare Group Inc. (DSKX), a leading developer of personal care products, announced today the launch of Spectral.DNC-N, the first product to incorporate the proprietary Nanoxidil compound, a powerful, gentle, nondrug alternative to minoxidil.
The new product is formulated to help stimulate hair across the entire scalp. It employs the Nanosome-encapsulation system — proprietary to the company’s DS Laboratories brand — to transport ingredients deeper into follicles for more effective results.
Spectral.DNC-N is the latest addition to the Spectral line, the first topical treatment series to address more than 20 potential causes of hair thinning and loss. Spectral products target these challenges with multiple bioactive ingredients to promote follicle rejuvenation throughout the entire scalp, as minoxidil does at the vertex.
The new formula was created to surpass the results obtained from older products. The innovative, nondrug biotechnology is lightweight, easy to use, and does not leave a heavy, greasy, or unsightly residue, which is common with mass-market hair-growth products.
In the hair follicle, Spectral.DNC-N generates adenosine triphosphate, the universal currency of bioenergy, and deposits a multitude of key compounds via sophisticated delivery systems. The formula is anti-inflammatory and antihormonal and delivers hydration, nutrition, stimulation, and rejuvenation.
New Nanoxidil 5%, a key compound in the product, has a lower molecular weight and does not require the chemical solvents that often irritate scalp. It works well for women with noticeable thinning and for men in the early or moderate stages of thinning. It benefits users with receding hairlines or patchy eyebrows and serves as an overall preventative therapy.
Uniquely lightweight and comfortable to use, Spectral.DNC-N contains procyanidin B-2 (apple polyphenol) to encourage hairline as well as vertex growth, retinol for better absorption, adenosine for cellular repair, patented Aminexil(R) to counter perifollicular fibrosis, copper peptides to fight scalp inflammation, and herbal extracts to support a healthy and comfortable overall condition.
About DS Healthcare Group
DS Healthcare Group Inc. leads in the development of biotechnology for topical, and nutritional therapies. It markets through online and specialty retailers, distributors, cosmetics wholesalers, and salons. Its brands include DS Laboratories (www.DSLaboratories.com), Sigma Skin (www.SigmaSkin.com), Polaris Research Laboratories (www.PolarisReserachLabs.com) and The Pure Guild (www.ThePureGuild.com).
Forward-looking statements
Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies, and are generally preceded by words such as “future,” “plan” or “planned,” “expects,” or “projected.” These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company’s control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing and marketing products, intense competition, and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available at http://www.sec.gov.